Phase IIa trial of fingolimod for amyotrophic lateral sclerosis demonstrates acceptable acute safety and tolerability

INTRODUCTION: Immune activation has been implicated in progression of amytrophic lateral sclerosis (ALS). Oral fingolimod reduces circulating lymphocytes. The objective of this phase IIa, randomized, controlled trial was to test the short‐term safety, tolerability, and target engagement of fingolimo...

Descripción completa

Detalles Bibliográficos
Autores principales: Berry, James D., Paganoni, Sabrina, Atassi, Nazem, Macklin, Eric A., Goyal, Namita, Rivner, Michael, Simpson, Ericka, Appel, Stanley, Grasso, Daniela L., Mejia, Nicte I., Mateen, Farrah, Gill, Alan, Vieira, Fernando, Tassinari, Valerie, Perrin, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5724488/
https://www.ncbi.nlm.nih.gov/pubmed/28662296
http://dx.doi.org/10.1002/mus.25733

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5724488/
https://www.ncbi.nlm.nih.gov/pubmed/28662296
http://dx.doi.org/10.1002/mus.25733

Ejemplares similares